Episode 60: Improving Care and Raising Awareness for NMOSD
Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Friedmann Paul, MD. [LISTEN TIME: 27 minutes]
Episode 60 of the NeurologyLive®
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.
Episode 60, "Improving Care and Raising Awareness for NMOSD," features an exclusive interview with Friedmann Paul, MD, head, Clinical Neuroimmunology Research Group, NeuroCure Clinical Research Center, and head, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité–Universitätsmedizin Berlin. He shared his perspective on the state of care in neuromyelitis optica spectrum disorder (NMOSD), the need to raise awareness for symptomatic care and patient challenges, and the potential of novel therapeutic approaches to improve care and possibly cure the disorder.
The stories highlighted in this episode's Neurology News Minute can be found here:
Donepezil Transdermal System Wins FDA Approval to Treat Alzheimer Disease Dementia Sarepta Details Phase 3 EMBARK Study in DMD Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder
EPISODE BREAKDOWN
2:00 – State of diagnosis and care for NMOSD and similar disorders
6:00 – Role of NMOSD Awareness Month and advocacy efforts
8:45 – Current challenges with symptomatic management
11:20 – Multidisciplinary communication, coordination, and collaboration
13:05 – Neurology News Minute
16:45 – The potential of self-tolerization and curing NMOSD
19:05 – Nonpharmacologic approaches to care
20:40 – The need to improve physician awareness and education
22:45 – Advice for communicating the diagnosis to patients
24:45 – The need for patient advocacy groups
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
Pathophysiology of Myasthenia GravisSeptember 18th 2025
